'60 Minutes' Features Two High School Seniors Who Solved 'Impossible' Mathematical Puzzle
Identity of Biden Fanboy on Election Panel Exposed and It Explans Everything
President Biden Awards Presidential Medal of Freedom to Greatest Speaker in History
Twitter Tries to Get to the Bottom of Biden's Walk with Some Solid...
ASU Students Arrested During Protests Won't Be Able to Finish Final Exams
Just for Fun: Some of the Best Tweets Leading Up to the 'Kentucky...
Student Protesters Trash Car That ‘Targeted’ Them; ‘This Wasn’t an Accident’
Protestors Compare Campus Riots to 1968 Movement but Americans Aren't Buying It
Covington 2.0? The Hill Says GOP Rep. Applauds Counter-Protesters Who Taunted Black Woman
Almost Snakes on a Plane? Miami TSSSsssSSSA Snags a Bag of Snakes From...
Biden Reminds Us to Vote for the Candidate Who Ignores SCOTUS Rulings in...
White House Isn't Finished Trying to Milk Every Ounce of Cringe Out of...
WOMP WOMP! Hims Stock Tanks After CEO Praises 'Moral Courage' of Antisemitic Campus...
'Public Assembly': Watch Police Harass Billboard Chris, Anna McGovern for Wearing a Sign...
AP Review of Star Wars Actor's Meeting With Biden Doesn't Match the Readout...

Christina Pushaw busts the AP for acknowledging a COVID treatment fact they shamed Ron DeSantis for pointing out just a few months ago

Yesterday, the Associated Press’ Matthew Perrone reported a possible setback for a couple of COVID19 treatments, including Regeneron.

Advertisement

More from the AP:

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain.

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new omicron-targeting antibodies, those aren’t expected to launch for at least several months.

The fact that Regeneron may not be as effective against the omicron variant as it’s been against others is noteworthy enough. But Gov. Ron DeSantis’ press secretary Christina Pushaw finds something else noteworthy, too:

Things sure have changed, haven’t they? Recall this past August, when the AP was entertaining the idea that DeSantis was promoting sketchy Regeneron in some kind of quid pro quo scheme because one of his top donors had invested money in Regeneron, making DeSantis shady AF and not to be trusted.

Advertisement

Pushaw called out the AP then.

Just like she’s calling out the AP now.

We’ve got whiplash.

And Pushaw’s got one last question for the AP:

Join the conversation as a VIP Member

Recommended

Trending on Twitchy Videos

Advertisement
Advertisement
Advertisement